About Endocyte Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte’s lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration-resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma.
Endocyte Announces Pricing of Public Offering of Common Stock GlobeNewswire•February 28, 2018 WEST LAFAYETTE, Ind., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the pricing of an underwritten registered public offering of 17,857,143 shares of its common stock at a price to the public of $4.20 per share. In addition, Endocyte granted the underwriters a 30-day option to purchase up to an additional 2,678,571 shares of its common stock on the same terms and conditions. All shares of common stock sold in the offering are being sold by Endocyte. Endocyte expects to close the offering on or about March 2, 2018, subject to the satisfaction of customary closing conditions.
